American Century Companies Inc. lessened its position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 27.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 37,840 shares of the biopharmaceutical company’s stock after selling 14,144 shares during the quarter. American Century Companies Inc. owned approximately 0.10% of Puma Biotechnology worth $3,740,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in PBYI. Janus Henderson Group PLC grew its position in Puma Biotechnology by 1.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,890,901 shares of the biopharmaceutical company’s stock valued at $226,435,000 after purchasing an additional 33,270 shares during the period. Perceptive Advisors LLC lifted its stake in Puma Biotechnology by 26.0% during the 3rd quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock valued at $110,627,000 after acquiring an additional 190,500 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in Puma Biotechnology by 265.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock valued at $57,743,000 after acquiring an additional 350,300 shares in the last quarter. Emerald Advisers Inc. PA raised its stake in shares of Puma Biotechnology by 16.5% during the 3rd quarter. Emerald Advisers Inc. PA now owns 370,035 shares of the biopharmaceutical company’s stock worth $44,312,000 after purchasing an additional 52,355 shares during the period. Finally, Emerald Mutual Fund Advisers Trust raised its stake in shares of Puma Biotechnology by 17.4% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 291,146 shares of the biopharmaceutical company’s stock worth $34,865,000 after purchasing an additional 43,108 shares during the period.
Several equities research analysts recently weighed in on PBYI shares. Royal Bank of Canada decreased their price objective on Puma Biotechnology to $77.00 and set a “sector perform” rating for the company in a report on Wednesday, January 24th. Credit Suisse Group reduced their target price on Puma Biotechnology from $147.00 to $106.00 and set an “outperform” rating for the company in a report on Wednesday, January 24th. Citigroup reaffirmed a “buy” rating and set a $164.00 target price on shares of Puma Biotechnology in a report on Wednesday, January 3rd. ValuEngine lowered Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, Zacks Investment Research upgraded Puma Biotechnology from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $107.00.
Puma Biotechnology Inc (PBYI) traded up $9.30 during midday trading on Friday, hitting $71.05. The stock had a trading volume of 3,984,062 shares, compared to its average volume of 1,210,000. The stock has a market capitalization of $3,070.00, a PE ratio of -9.04 and a beta of 0.26. Puma Biotechnology Inc has a 52-week low of $28.35 and a 52-week high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.27. The business had revenue of $21.60 million for the quarter, compared to the consensus estimate of $20.83 million. During the same period in the previous year, the company earned ($1.22) earnings per share. equities analysts expect that Puma Biotechnology Inc will post -4.69 earnings per share for the current year.
In related news, SVP Richard Paul Bryce sold 1,860 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $172,515.00. Following the completion of the sale, the senior vice president now owns 25,379 shares in the company, valued at $2,353,902.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alan H. Auerbach sold 10,692 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $991,683.00. Following the sale, the insider now owns 4,155,931 shares of the company’s stock, valued at approximately $385,462,600.25. The disclosure for this sale can be found here. 21.10% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Puma Biotechnology Inc (PBYI) Shares Sold by American Century Companies Inc.” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/03/03/american-century-companies-inc-has-3-74-million-position-in-puma-biotechnology-inc-pbyi.html.
Puma Biotechnology Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Puma Biotechnology and related companies with MarketBeat.com’s FREE daily email newsletter.